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Background: Little is known about whether changes in health-related quality of life (HRQoL) scores from baseline during
treatment also predict survival, which we aim to investigate in this study.
Methods: We analysed data from 391 advanced non-small-cell lung cancer (NSCLC) patients enrolled in the EORTC 08975 study,
which compared palliative chemotherapy regimens. HRQoL was assessed at baseline and after each chemotherapy cycle using
the EORTC QLQ-C30 and QLQ-LC13. The prognostic significance of HRQoL scores at baseline and their changes over time was
assessed with Cox regression, after adjusting for clinical and socio-demographic variables.
Results: After controlling for covariates, every 10-point increase in baseline pain and dysphagia was associated with 11% and 12%
increased risk of death with hazard ratios (HRs) of 1.11 and 1.12, respectively. Every 10-point improvement of physical function at
baseline (HR¼ 0.93) was associated with 7% lower risk of death. Every 10-point increase in pain (HR¼ 1.08) was associated with 8%
increased risk of death at cycle 1. Every 10-point increase in social function (HR¼ 0.91) at cycle 2 was associated with 9% lower risk
of death.
Conclusions: Our findings suggest that changes in HRQoL scores from baseline during treatment, as measured on subscales of
the EORTC QLQ-C30 and QLQ-LC13, are significant prognostic factors for survival.
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Lung cancer is the most common cancer worldwide, in terms of
both incidence and mortality. In 2008, there were 1.61 million new
cases, and 1.38 million deaths due to lung cancer. The highest rates
are in Europe and North America (Ferlay et al, 2010). Lung cancer
patients experience a variety of distressing symptoms, which are
usually present before diagnosis and continue throughout the
course of the disease and treatment, adversely affecting functional
status and health-related quality of life (HRQoL) (Akin et al, 2010;
Tishelman et al, 2010).
With the availability of reliable and valid self-report ques-
tionnaires, HRQoL has become recognised as being important for
treatment decision making (Basch et al, 2012). The importance of
incorporating HRQoL into cancer research and policy formation
has been emphasised by major policy making and regulatory
entities (Lipscomb et al, 2007) such as the US National Cancer
Institute (National Cancer Institute, 2008), US Food and Drug
Administration (Johnson et al, 2003; United States Department of
Health and Human Services, Food and Drug Administration
(FDA), Center for Drug Evaluation and Research (CDER), Center
for Biologics Evaluation and Research (CBER), Center for Devices
and Radiological Health (CDRH), 2007), The European Medicines
Agency(EMEA/CHMP/EWP/139391/2004, 2004). There is also
growing agreement amongst healthcare professionals and research-
ers that treatment efficacy should be judged by effects on both
quantity and quality of life (Braun et al, 2011a).
Patients with lung cancer often experience an ongoing
deterioration in HRQoL (Gralla, 2004). The majority of lung
cancer patients (approximately 90%) are diagnosed with non-
small-cell lung cancer (NSCLC) and most patients with NSCLC
present with locally advanced or metastatic disease, which is
incurable with existing treatment modalities (Kvale et al, 2003).
Many studies and meta-analyses have demonstrated that a
patient’s baseline HRQoL can predict overall survival (OS) across
different cancer types, independent of socio-demographic and
other clinical prognostic factors (Ganz et al, 1991; Herndon et al,
1999; Maione et al, 2005; Gotay et al, 2008; Quinten et al, 2009;
Braun et al, 2011b). A recent paper by (Sloan et al, 2012)
demonstrated in NSCLC patients that overall HRQoL measured by
a simple, single item at the time of diagnosis is a significant
prognostic factor for survival. However, few studies have
investigated the added value of change in HRQoL from baseline
over time (Eton et al, 2003; Gupta et al, 2012). Potentially, the
short-term evolution of HRQoL could improve the predictive
accuracy, although there is uncertainty about the optimal time-
frame. The current study investigated whether changes in HRQoL
scores from baseline over time were associated with survival,
independent of baseline HRQoL scores, in patients with advanced
NSCLC.
PATIENTS AND METHODS
Data collection. EORTC 08975 (NCT00003589) was a prospec-
tive, multicentre, randomised, non-blinded, phase III trial invol-
ving 29 institutions and 480 enrolled patients with advanced
NSCLC. All patients had histologically or cytologically confirmed
NSCLC stage IIIB or stage IV disease according to the previous
staging system (1997) of the American Joint Committee on Cancer
( Mountain, 1997). Patients were randomised to receive paclitaxel
175 mg m 2 followed by cisplatin 80 mg m 2 on day 1 (arm A),
gemcitabine 1250 mg m 2 on days 1 and 8 and cisplatin
80 mg m 2 on day 1 (arm B), or paclitaxel 175 mg m 2 on day
1 followed by gemcitabine 1250 mg m 2 on days 1 and 8 (arm C).
Treatment cycles were repeated every three weeks. Results showed
no difference in OS by arm. These treatments were generally well
tolerated with similar outcomes in most HRQoL parameters.
Further details of the trial design, conduct and results are reported
elsewhere ( Smit et al, 2003).
Health-related quality of life was assessed at baseline (i.e., before
treatment), at the end of each treatment cycle, then every 6 weeks
until progression of the disease (PD), at PD and thereafter every 3
months until death using the European Organisation for Research
and Treatment of Cancer Quality of Life Questionnaire Core 30
(EORTC QLQ-C30, version 3  0) in conjunction with the EORTC
lung cancer module (QLQ-LC13). The EORTC QLQ-C30 contains:
five functioning scales (physical, role, emotional, cognitive and
social), nine symptom scales (fatigue, pain, dyspnoea, appetite loss,
sleep disturbance, constipation, diarrhoea, nausea and financial
difficulties) and the global health status/QOL scale. The LC13
module is meant for use in lung cancer patients, regardless of
disease stage and treatment modality (Bergman et al, 1994). The
module contains eight scales assessing lung cancer-associated
symptoms: dyspnoea, pain, coughing, sore mouth, dysphagia,
peripheral neuropathy, alopecia and haemoptysis. For both
instruments, raw scores were linearly transformed to a scale from
0 to 100 according to standard scoring procedures (Aaronson et al,
1993). High scores indicate better HRQoL for the functional scales
and the global health status/QOL scale but worse HRQoL for the
symptom scales. Both instruments have been extensively tested for
reliability and validity (Bergman et al, 1994; Osoba et al, 1994;
Groenvold et al, 1997). The minimum clinically meaningful
important difference on the QLQ-C30 and LC13 scales is at least
10 points (Osoba et al, 1998).
The total number of scales for the EORTC QLQ-C30 and the
LC13 is 23. To reduce the multidimensionality of the data, we
included the following scales based on published evidence (Efficace
et al, 2006) by excluding a priori, the HRQoL scales that were
expected to have no prognostic value and had high intercorrelation
with other scales: global quality of life, emotional, social and
physical functioning, nausea and vomiting, pain, appetite loss,
dyspnoea (combined scale constructed from the average of the
QLQ-C30 and the QLQ-LC13 dyspnoea items), coughing and
dysphagia. Additional socio-demographic and biomedical variables
considered in this study were age (continuous), gender, stage of
disease (IIIB vs IV), histological subtype (squamous vs non-
squamous) and WHO performance status (PS; 0–1 vs 2).
Statistical analysis. The analyses were split into two parts. First,
the relationship between baseline HRQoL and OS was investigated
for patients with a valid completed baseline HRQoL measure.
Second, the relationship between change in HRQoL scores from
baseline to the end of each cycle of treatment and survival was
assessed for the same patient cohort. Three different change scores
were calculated by subtracting the baseline score from the scores at
the end of the 1st, 2nd and 3rd cycle of treatment (Braun et al,
2011a). The analysis was limited to changes from baseline up to
cycle 3, as available patient numbers declined over time through
attrition due to death and treatment withdrawal. Spearman rank
correlation was used to summarise the relationships between
explanatory variables.
The outcome variable was OS, measured from the date of
randomisation until the date of death (due to any cause), and
calculated using the Kaplan–Meier method. The prognostic value
of individual socio-demographic, clinical and HRQoL variables was
evaluated using univariate Cox proportional hazards (Cox, 1972)
models (CPHM). Multivariate CPHM were then performed to
evaluate the joint prognostic significance of variables that were
shown to be univariately prognostic at the 5% level of significance.
The randomised protocol treatment was included as a stratification
factor.
We used a stepwise method for the model selection. Stepwise
procedures can reduce the problem of multicollinearity because
two highly correlated predictors will normally not both be entered
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in the model (Braun et al, 2011a). The assumptions from the
CPHM for both the univariate and multivariate analyses were
assessed graphically. The prognostic value was assessed via the
hazard ratio (HR), its 95% CI and the P-value of the Wald
w2-statistic. A significance level of 5% was used as a threshold for
variable selection. The reported HR of the HRQoL scales was
rescaled to represent a clinically meaningful important difference of
10 points (Osoba et al, 1998). Potential influence of sample bias and
multicollinearity on the results was investigated using the bootstrap
resampling technique (Suaerbrei and Schumacher, 1992). This
technique generates a number of samples (each the same size as the
original data set), by randomly selecting patients and replacing
them before selecting the next patient (i.e., bootstrap resampling).
Cox regression was then fitted to each of these datasets using
automatic stepwise selection (entry level of a¼ 0.05). We calculated
the model selection probabilities based on how many times a
permissible model was selected in the bootstrap samples. These
probabilities were then used as weights to obtain weighted averaged
parameters. All analyses were carried out with the SAS Software
version 9.4 (SAS Institute Inc., Cary, NC, USA).
RESULTS
Between August 1998 and July 2000, 480 patients were randomly
assigned: 159 (group A), 160 (group B) and 161 (group C). Of
these, 391 (81.5%) had a valid completed baseline HRQoL
questionnaire. Only patients with valid baseline scores were
considered for the analyses (group A (133), group B (133) and
group C (125)).
Patient characteristics at baseline in terms of stage, histology
and treatment and performance status were well balanced between
patients for whom HRQoL data were available or not (Efficace
et al, 2006). There was a significant difference in median survival
between patients with and without baseline HRQoL data (data not
shown). There were 302 deaths reported. Given the rule of thumb
that CPHM should be used with a minimum of 10 or less outcome
events per predictor (Concato et al, 1995; Peduzzi et al, 1995, 1996;
Vittinghoff and McCulloch, 2007), this allows for an adequately
robust analysis. The correlation coefficient between explanatory
variables in absolute value at baseline ranges between 0.03 and
0.50.
Association between baseline HRQoL and survival. Table 1
describes the results of univariate Cox regression analysis of a
patient’s clinical and HRQoL scores at baseline. Gender and WHO
PS (1–2 vs 3) were significantly associated with survival, whereas
age and histological subtype were not. The clinical stage at
diagnosis was borderline significant. The median survival for
women and men was 9.6 and 7.2 months, respectively, P¼ 0.03.
The median survival for patients with good and poor WHO PS was
8.9 and 3.2 months, respectively, Po0.001. All the selected baseline
HRQoL scores measured with the EORTC QLQ-C30 and the LC13
subscales were predictive of survival except for emotional
functioning for the QLQ-C30. The HRs of these HRQoL scales
at baseline were similar in magnitude (0.86 (physical function)—
1.16 (dysphagia)) after adjusting for age, gender, WHO PS,
histology and stage of disease.
The Cox multivariate regression including WHO PS, gender
and the ten HRQoL scores retained WHO PS, gender, physical
functioning, pain and dysphagia after application of the selection
procedure. To assess how much prognostic value HRQoL can add
to a clinical model, the model selection process was repeated with
WHO PS, gender, age, clinical stage of disease and histological
subtype forced into the model. Table 2 depicts the results of the
final model. From Table 2, every 10-point increase in baseline
physical functioning score was associated with a 7% lower risk of
death (HR, 0.93; 95% CI, 0.88–0.98), and every 10-point increase in
baseline pain was associated with an 11% increased risk of death
(1.11, 1.06–1.15). Also for every 10-point increase, the dysphagia
score at baseline was associated with a 12% increased risk of death
Table 1. Univariate Cox regression analysis of survival at baseline
Unadjusted Adjusted
Explanatory variables HRs (95% CI) P-values HRs (95% CI) P-values
Socio-demographic and clinical variables
Age (continuous) 1.01 (0.81–1.25) 0.95 — —
Sex (men vs women) 0.79 (0.63–0.99) 0.04c — —
WHO PS (good vs poor) 2.08 (1.49–2.91) o0.0001c — —
Histological subtype (squamous vs non-squamous) 0.98 (0.76–1.26) 0.87 — —
Clinical stage (IIIB vs IV) 1.30 (1.00–1.70) 0.05 — —
HRQoL variablesa
Global health status/QOL 0.88 (0.84–0.92) o0.0001c 0.88 (0.84–0.92) o0.0001c
Physical functioning 0.86 (0.83–0.90) o0.0001c 0.87 (0.83–0.92) o0.0001c
Emotional functioning 0.96 (0.92–1.00) 0.06 0.95 (0.91–0.99) 0.02c
Social functioning 0.92 (0.89–0.96) o0.0001c 0.92 (0.89–0.96) o0.0001c
Nausea/vomiting 1.07 (1.01–1.13) 0.02c 1.06 (1.00–1.12) 0.04c
Pain 1.13 (1.10–1.17) o0.0001c 1.13 (1.10–1.17) o0.0001c
Dyspnoeab 1.12 (1.05–1.19) 0.0003c 1.14 (1.07–1.21) o0.0001c
Appetite loss 1.07 (1.04–1.11) o0.0001c 1.07 (1.03–1.11) 0.0001c
Coughing 1.05 (1.01–1.09) 0.02c 1.05 (1.01–1.09) 0.02c
Dysphagia 1.15 (1.07–1.23) o0.0001c 1.16 (1.08–1.24) o0.0001c
Abbreviations: CI¼ confidence interval; HRs¼hazard ratios; HRQoL¼health-related quality of life; PS¼performance status; QOL¼quality of life. The analysis was stratified by treatment.
aHRs correspond to every 10-point increase for the EORCT QLQ-C30 and QLQ-LC13 scales.
bCombined scale constructed from the average of the of the EORTC QLQ-C30 and the QLQ-LC13 dyspnoea scales.
cP-values o0.05.
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(1.12, 1.04–1.20). We detected no violations of the proportionality
assumptions for the variables investigated in our model.
Association between changes from baseline HRQoL and
survival. Univariate analysis of the change scores revealed that
there was a correlation (HR¼ 0.97 (pain)—1.09 (nausea/vomit-
ing)) between the three changes from baseline scores (i.e., baseline
to 1st cycle, 2nd cycle and 3rd cycle of treatment) and the
corresponding actual baseline value. Therefore, to account for
potential confounding, the baseline value was added to the
univariate and multivariate models investigating the association
between changes from baseline HRQoL and OS.
Table 3 describes the univariate analysis of changes in scores
from baseline to each chemotherapy cycle up to cycle 3. Pain and
coughing were predictive for survival at cycle 1. At cycle 2, only
social functioning was predictive for survival. At cycle 3, nausea/
vomiting was predictive for survival. The correlation coefficient
between explanatory variables in absolute value ranges between
0.004–0.46, 0.004–0.40 and 0.01–0.42 at cycle 1, 2 and 3,
respectively.
In Table 4, pain at cycle 1 and social functioning at cycle 2
remained statistically significant in the multivariate analysis. No
other HRQoL variables were statistically significant. Every 10-point
increase in the pain scale from baseline to cycle 1 was associated
with an 8% increase risk of death. Every 10-point increase from
baseline to cycle 2 in the social functioning scale was associated
with a 9% lower risk of death. There was no evidence of non-
proportional hazards in the multivariate models.
Bootstrap model resampling. In order to have greater insight into
the stability of the final Cox multivariate models for prognostic
value of change in HRQoL from baseline, and thus evaluate the
importance of a single variable being included as an independent
factor, we conducted a bootstrap resampling technique based on
5,000 bootstrap-generated simulation datasets. The highest inclu-
sion frequencies at baseline were pain (97.4%), gender (85.1%),
dysphagia (78.3%), performance status (61.1%) and physical
functioning (53.3%); at cycle 1, pain (72.5%), gender (65.4%),
performance status (45.5%) and coughing (24.7%); at cycle 2,
gender (68.1%), age (60.9%), social functioning (53.7%) and stage
of disease (46.4%); and at cycle 3, age (68.4%), nausea/vomiting
(44.5%) and gender (41.0%). The recorded inclusion frequencies
highlight the importance of a single variable being included as an
independent factor in the model. This evidence further strengthens
the results obtained with the classical Cox regression analysis.
DISCUSSION
The original analysis of this large randomised trial identified (in
the multivariate analysis) WHO PS as the only key factor
predicting survival in this population (Smit et al, 2003). (Smit
et al, 2003) showed that patients with WHO PS 0–1 had a median
survival of 8.5 months, whereas those with WHO PS 2 had a
median survival of 3.3 months (Po0.001). In our analysis and also
that of (Efficace et al, 2006), on the subgroup of patients with
HRQoL data, female gender also predicted higher OS. A previously
published analysis of 2531 advanced NSCLC patients also showed
that female gender and good WHO PS were favourable
independent prognostic factors for survival (Albain et al, 1991).
However, (Smit et al, 2003) analysis did not include HRQoL
variables. The present analysis identified patients’ self-reported
physical functioning (at baseline), pain (at baseline and change
from baseline to cycle 1) and social function (change from baseline
to cycle 2) as further prognostic factors for survival. We should
note that the magnitude of the HRs of the EORTC QLQ-C30 and
LC13 scales are smaller than those for the (categorised) clinical
variables. The finding of physical functioning and pain predicting
survival in lung cancer has previously been reported (Ganz et al,
1991; Herndon et al, 1999; Movsas et al, 2009).
However, we observed a counter-intuitive finding in the
univariate analysis: self-reported improvement over time (for the
functional scales and global health status) was associated with a
higher risk of death. (Braun et al, 2011a) also reported that an
improvement in social functioning at 3 months was independently
associated with a worse survival. Change score analyses can be
biased by floor and ceiling effects at baseline, as those with extreme
scores cannot improve or deteriorate beyond the maximum or
minimum scores. In our sample, patients who reported a high level
of symptoms at trial entry had a poor prognosis, but tended to
report better outcomes over time (either through concomitant care,
habituation or statistical regression to the mean). The reverse was
seen in patients entering the trial with very good self-reported
scores.
Table 2. Multivariate Cox regression analyses of survival for socio-demographic and clinical data and for socio-demographic, clinical and HRQoL data at
baseline
Cox model for socio-demographic and
clinical data only
Cox model for socio-demographic, clinical and
HRQoL data combined
Explanatory Variables HRs (95% CI) P-values HRs (95% CI) P-values
Socio-demographic and clinical variables
Age (continuous) 0.99 (0.98–1.00) 0.06 0.99 (0.98–1.01) 0.21
Sex 0.75 (0.59–0.95) 0.01b 0.67 (0.52–0.85) 0.001b
WHO PS 2.09 (1.49–2.94) o0.0001b 1.53 (1.04–2.26) 0.03b
Histological subtype (squamous vs non-squamous) 0.93 (0.71–1.21) 0.46 0.99 (0.75–1.31) 0.97
Clinical stage (IIIB vs IV) 1.25 (0.97–1.62) 0.04b 1.18 (0.90–1.56) 0.24
HRQoL variablesa
Physical function — — 0.93 (0.88–0.98) 0.01b
Pain — — 1.11 (1.06–1.15) o0.0001b
Dysphagia — — 1.12 (1.04–1.20) 0.002
Abbreviations: CI¼ confidence interval; HRs¼hazard ratios; HRQoL¼health-related quality of life; PS¼performance status. The analysis was stratified by treatment.
aHRs corresponds to every 10-point increase for the EORCT QLQ-C30 and QLQ-LC13 scales.
bP-values o0.05.
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Our results have important implications for both clinical and
research practices. They reinforce the notion that baseline HRQoL
scores are prognostic and suggest that change from baseline over
time in HRQoL scores, as measured on subscales of the EORTC
QLQ-C30 and LC13, may provide additional prognostic value for
survival. Thus, baseline HRQoL, in addition to clinical variables,
should be taken into consideration when planning treatment. Also,
inclusion of baseline HRQoL as a stratification factor could
increase trial efficiency, create more homogeneous treatment
groups and improve understanding of trial results. Our work
suggests that the regular HRQoL assessments during the course of
treatment could be an early signal of patient deterioration, and
raises the hypothesis that interventions to improve pain, physical
functioning, dysphagia and social function could have potential to
improve survival outcomes. Appropriate care procedures should be
taken when there is an indication of a patient’s HRQoL
deterioration. However, the utility of this approach to patient
management should be investigated in prospective studies in
NSCLC cancer patients.
Our study is a secondary analysis with several limitations. The
median survival of the patients who provided HRQoL baseline
data, in the original trial, was higher than that of patients who did
not. Although our observed baseline HRQoL scores were similar to
other groups of patients with the same disease (Scott et al, 2008),
such missing data, which are common in HRQoL studies, may
restrict the generalisability of our findings. It is possible that our
study sample might reflect patients with a better baseline health
condition who experienced fewer symptoms.
In conclusion, our findings lend further support to the growing
body of literature that suggest that baseline HRQoL, as well as
change from baseline over time in HRQoL, as measured on
subscales of the EORTC QLQ-C30 and LC13, contains added
prognostic value for survival in advanced NSCLC.
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